The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Updates from IMbrave 150 in HCC

Name: Updates from IMbrave 150 in HCC
Uploaded: 2020-07-03T00:00:00Z
Duration: 4 min 5 s
Description: Daneng Li, MD, of City of Hope National Medical Center, Duarte, CA, discusses results from older adults enrolled in IMbrave150 (NCT03434379), a study investigating atezolizumab and bevacizumab vs sorafenib for unresectable hepatocellular carcinoma (HCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Daneng Li • 3 Jul 2020

ESMO WCGIC 2020

Gastrointestinal Cancer Liver Cancer Antibodies Atezolizumab Bevacizumab Sorafenib

IMbrave150

Daneng Li, MD, of City of Hope National Medical Center, Duarte, CA, discusses results from older adults enrolled in IMbrave150 (NCT03434379), a study investigating atezolizumab and bevacizumab vs sorafenib for unresectable hepatocellular carcinoma (HCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).